Literature DB >> 19084416

Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity.

Ahmed M Galal1, Waseem Gul, Desmond Slade, Samir A Ross, Shixia Feng, Melinda G Hollingshead, Michael C Alley, Gurmeet Kaur, Mahmoud A ElSohly.   

Abstract

Twelve artemisinin acetal dimers were synthesized and tested for antitumor activity in the National Cancer Institute (NCI) in vitro human tumor 60 cell line assay, producing a mean GI(50) concentration between 8.7 (least active) and 0.019 microM (most active). The significant activity of the compounds in this preliminary screen led to additional in vitro antitumor and antiangiogenesis studies. Several active dimers were also evaluated in the in vivo NCI hollow fiber assay followed by a preliminary xenograft study. The title compounds were found to be active against solid tumor-derived cell lines and showed good correlation with other artemisinin-based molecules in the NCI database. The dimers were also evaluated for their antimalarial and antileishmanial activities. The antimalarial activity ranged from 0.3 to 32 nM (IC(50)), compared to 9.9 nM for artemisinin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084416     DOI: 10.1016/j.bmc.2008.11.050

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  14 in total

Review 1.  Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.

Authors:  Yulin Ren; Jianhua Yu; A Douglas Kinghorn
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 2.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

3.  Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.

Authors:  Colm Morrissey; Byron Gallis; Jeffrey W Solazzi; Byung Ju Kim; Roman Gulati; Funda Vakar-Lopez; David R Goodlett; Robert L Vessella; Tomikazu Sasaki
Journal:  Anticancer Drugs       Date:  2010-04       Impact factor: 2.248

4.  Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers.

Authors:  Desmond Slade; Ahmed M Galal; Waseem Gul; Mohamed M Radwan; Safwat A Ahmed; Shabana I Khan; Babu L Tekwani; Melissa R Jacob; Samir A Ross; Mahmoud A Elsohly
Journal:  Bioorg Med Chem       Date:  2009-10-30       Impact factor: 3.641

5.  Large-scale investigation of Leishmania interaction networks with host extracellular matrix by surface plasmon resonance imaging.

Authors:  Marie Fatoux-Ardore; Franck Peysselon; Anthony Weiss; Patrick Bastien; Francine Pratlong; Sylvie Ricard-Blum
Journal:  Infect Immun       Date:  2013-11-25       Impact factor: 3.441

6.  Dihydroartemisinin: a new story of an old drug against Schistosoma mansoni infection.

Authors:  Hong-Jun Li; Fu-Liang Xu; Yun-Hai Wang; Zheng-Jun Yi; Wei Wang
Journal:  Parasitol Res       Date:  2013-10-22       Impact factor: 2.289

7.  Perspective: Opportunities in recalcitrant, rare and neglected tumors.

Authors:  Beverly A Teicher
Journal:  Oncol Rep       Date:  2013-07-02       Impact factor: 3.906

8.  (1R,3S,4R,4aS,7R,7aS,10R,12aR)-3-Azido-4,7,10-trimethyl-1,10-epidioxy-per-hydropyrano[4,3-j][1,2]benzodiox-epine.

Authors:  Lijun Xie; Xin Zhai; Jian Zuo; Yanfang Zhao; Ping Gong
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-06-26

9.  A mitochondria-targeting artemisinin derivative with sharply increased antitumor but depressed anti-yeast and anti-malaria activities.

Authors:  Chen Sun; Yu Cao; Pan Zhu; Bing Zhou
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

10.  pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members.

Authors:  Yitong J Zhang; Byron Gallis; Michio Taya; Shusheng Wang; Rodney J Y Ho; Tomikazu Sasaki
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.